Pola-R2 in Newly Diagnosed Non-fit Elderly DLBCL Patients

• Status: Recruiting
• Trial end date: 2027-10-24
• Target enrollment: 0
• Participant gender: All

Summary

This is a prospective, single-arm, phase II study, and the purpose of this study is to evaluate the efficacy and safety of Pola-R2 regimen in newly diagnosed elderly diffuse large B cell lymphoma classified into un-fit or frail group by comprehensive geriatric assessment(CGA).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Yan Zhang, MD
• Collaborators: Chinese PLA General Hospital; Peking University First Hospital; Peking University Third Hospital
• Treatments: Lenalidomide; Polatuzumab vedotin; Rituximab

Criteria

Inclusion Criteria:

• The patient volunteered to participate in the study and signed the Informed Consent

• Histopathologically confirmed DLBCL and treatment naive(corticosteroids alone is not considered as a line of treatment)

• Age≥ 70 years old, and was un-fit or frail according to comprehensive geriatric assessment

• Adequate organ function and adequate bone marrow reserve

Exclusion Criteria:

• Coexisting malignancy other than lymphoma

• Active HBV infection

• Any instability of systemic disease, including but not limited to active infection (except local infection), severe cardiac, liver, kidney, or metabolic disease need therapy